Article | Published:

Supplementation of p40, a Lactobacillus rhamnosus GG-derived protein, in early life promotes epidermal growth factor receptor-dependent intestinal development and long-term health outcomes

Mucosal Immunologyvolume 11pages13161328 (2018) | Download Citation



The beneficial effects of the gut microbiota on growth in early life are well known. However, knowledge about the mechanisms underlying regulating intestinal development by the microbiota is limited. p40, a Lactobacillus rhamnosus GG-derived protein, transactivates epidermal growth factor receptor (EGFR) in intestinal epithelial cells for protecting the intestinal epithelium against injury and inflammation. Here, we developed p40-containing pectin/zein hydrogels for targeted delivery of p40 to the small intestine and the colon. Treatment with p40-containing hydrogels from postnatal day 2 to 21 significantly enhanced bodyweight gain prior to weaning and functional maturation of the intestine, including intestinal epithelial cell proliferation, differentiation, and tight junction formation, and IgA production in early life in wild-type mice. These p40-induced effects were abolished in mice with specific deletion of EGFR in intestinal epithelial cells, suggesting that transactivation of EGFR in intestinal epithelial cells may mediate p40-regulated intestinal development. Furthermore, neonatal p40 treatment reduced the susceptibility to intestinal injury and colitis and promoted protective immune responses, including IgA production and differentiation of regulatory T cells, in adult mice. These findings reveal novel roles of neonatal supplementation of probiotic-derived factors in promoting EGFR-mediated maturation of intestinal functions and innate immunity, which likely promote long-term beneficial outcomes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Hooper, L. V. Bacterial contributions to mammalian gut development. Trends Microbiol. 12, 129–34 (2004).

  2. 2.

    Gensollen, T., Iyer, S. S., Kasper, D. L. & Blumberg, R. S. How colonization by microbiota in early life shapes the immune system. Science 352, 539–44 (2016).

  3. 3.

    Blanton, L. V. et al. Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children. Science 351, 6275 (2016).

  4. 4.

    Haberman, Y. et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J. Clin. Invest. 124, 3617–33 (2014).

  5. 5.

    Michail, S. et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm. Bowel Dis. 18, 1799–1808 (2012).

  6. 6.

    Lopez-Serrano, P. et al. Environmental risk factors in inflammatory bowel diseases. Investigating the hygiene hypothesis: a Spanish case-control study. Scand. J. Gastroenterol. 45, 1464–71 (2010).

  7. 7.

    Hill, C. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–14 (2014).

  8. 8.

    Preidis, G. A. et al. Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology 140, 8–14 (2011).

  9. 9.

    Guandalini, S. Probiotics for prevention and treatment of diarrhea. J. Clin. Gastroenterol. 45(Suppl.), S149–S53 (2011).

  10. 10.

    Schwarzer, M. et al. Lactobacillus plantarum strain maintains growth of infant mice during chronic undernutrition. Science 351, 854–7 (2016).

  11. 11.

    Yan, F. et al. Neonatal colonization of mice with LGG promotes intestinal development and decreases susceptibility to colitis in adulthood. Mucosal Immunol. 10, 117–27 (2017).

  12. 12.

    Thomas, C. M. & Versalovic, J. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes 1, 148–63 (2010).

  13. 13.

    Vanderpool, C., Yan, F. & Polk, D. B. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm. Bowel Dis. 14, 1585–96 (2008).

  14. 14.

    Yan, F. et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132, 562–75 (2007).

  15. 15.

    Wang, L. et al. Activation of epidermal growth factor receptor mediates mucin production stimulated byp40, a Lactobacillus rhamnosus GG-derived protein. J. Biol. Chem. 289, 20234–44 (2014).

  16. 16.

    Wang, Y. et al. An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. Mucosal Immunol. 10, 373–84 (2017).

  17. 17.

    Yan, F. et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J. Clin. Invest. 121, 2242–53 (2011).

  18. 18.

    Yan, F. et al. A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor. J. Biol. Chem. 288, 30742–51 (2013).

  19. 19.

    Yarden, Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3–S8 (2001).

  20. 20.

    Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127–37 (2001).

  21. 21.

    Miettinen, P. J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337–41 (1995).

  22. 22.

    Hirai, C. et al. Trophic effect of multiple growth factors in amniotic fluid or human milk on cultured human fetal small intestinal cells. J. Pediatr. Gastroenterol. Nutr. 34, 524–28 (2002).

  23. 23.

    Nojiri, T. et al. Clinical significance of amphiregulin and epidermal growth factor in colostrum. Arch. Gynecol. Obstet. 286, 643–47 (2012).

  24. 24.

    Michalsky, M. P., Lara-Marquez, M., Chun, L. & Besner, G. E. Heparin-binding EGF-like growth factor is present in human amniotic fluid and breast milk. J. Pediatr. Surg. 37, 1–6 (2002).

  25. 25.

    Cheung, Q. C. et al. Generation of epidermal growth factor-expressing Lactococcus lactis and its enhancement on intestinal development and growth of early-weaned mice. Am. J. Clin. Nutr. 89, 871–79 (2009).

  26. 26.

    Sinha, A., Nightingale, J., West, K. P., Berlanga-Acosta, J. & Playford, R. J. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. 349, 350–57 (2003).

  27. 27.

    Dube, P. E. et al. Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J. Clin. Invest. 122, 2780–92 (2012).

  28. 28.

    Berni Canani, R. et al. Formula selection for management of children with cow’s milk allergy influences the rate of acquisition of tolerance: a prospective multicenter study. J. Pediatr. 163, 771–7 e771 (2013).

  29. 29.

    Seth, A., Yan, F., Polk, D. B. & Rao, R. K. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1060–G9 (2008).

  30. 30.

    Yoda, K. et al. Lactobacillus GG-fermented milk prevents DSS-induced colitis and regulates intestinal epithelial homeostasis through activation of epidermal growth factor receptor. Eur. J. Nutr. 53, 105–15 (2014).

  31. 31.

    Patel, R. M. et al. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am. J. Pathol. 180, 626–35 (2012).

  32. 32.

    Cerutti, A. & Rescigno, M. The biology of intestinal immunoglobulin A responses. Immunity 28, 740–50 (2008).

  33. 33.

    Talham, G. L., Jiang, H. Q., Bos, N. A. & Cebra, J. J. Segmented filamentous bacteria are potent stimuli of a physiologically normal state of the murine gut mucosal immune system. Infect. Immun. 67, 1992–2000 (1999).

  34. 34.

    Strober, W., Fuss, I. J. & Blumberg, R. S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20, 495–549 (2002).

  35. 35.

    Okayasu, I. et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694–702 (1990).

  36. 36.

    Pabst, O. New concepts in the generation and functions of IgA. Nat. Rev. Immunol. 12, 821–32 (2012).

  37. 37.

    Johansson, M. E., Sjovall, H. & Hansson, G. C. The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 10, 352–61 (2013).

  38. 38.

    Tanoue, T., Atarashi, K. & Honda, K. Development and maintenance of intestinal regulatory T cells. Nat. Rev. Immunol. 16, 295–309 (2016).

  39. 39.

    Vahabnezhad, E., Mochon, A. B., Wozniak, L. J. & Ziring, D. A. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J. Clin. Gastroenterol. 47, 437–9 (2013).

  40. 40.

    Land, M. H. et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115, 178–1 (2005).

  41. 41.

    Troyer, K. L. et al. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking egf, amphiregulin, and tgf-alpha. Gastroenterology 121, 68–78 (2001).

  42. 42.

    Xian, C. J. Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr. Rev. 28, 284–96 (2007).

  43. 43.

    Olszak, T. et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336, 489–93 (2012).

  44. 44.

    Cox, L. M. et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158, 705–21 (2014).

  45. 45.

    Rogier, E. W. et al. Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc. Natl. Acad. Sci. USA 111, 3074–9 (2014).

  46. 46.

    Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875–86 (2003).

  47. 47.

    Floch, M. H. et al. Recommendations for probiotic use—2015 update: proceedings and consensus opinion. J. Clin. Gastroenterol. 49(Suppl. 1), S69–S73 (2015).

  48. 48.

    Sanders, M. E. et al. An update on the use and investigation of probiotics in health and disease. Gut 62, 787–96 (2013).

  49. 49.

    Maldonado, J. et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J. Pediatr. Gastroenterol. Nutr. 54, 55–61 (2012).

  50. 50.

    Marzuillo, P., Guarino, S. & Perrone, L. Atopic eczema could be a cause and not an effect of cow’s milk protein allergy. J. Pediatr. Gastroenterol. Nutr. 58, e23 (2014).

  51. 51.

    Fuss, I. J. et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117, 78–1088 (1999).

  52. 52.

    Neurath, M. F. et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J. Exp. Med. 195, 1129–43 (2002).

Download references


This work was supported by National Institutes of Health (NIH) grant R01DK081134 and the Crohn’s & Colitis Foundation Senior Research Award (to F.Y.), NIH grants R01DK56008 and R01DK54993 and the Crohn’s & Colitis Foundation Senior Research Award (to D.B.P.), NIH grants R01DK58587, R01CA77955, and P01CA116087 (to R.M.P.), and National Natural Science Foundation of China Grant 81372982 (to F.H.), and core services performed through Vanderbilt University Medical Center’s Digestive Disease Research Center supported by NIH grant P30DK058404. Whole slide imaging was performed in the Digital Histology Shared Resource at Vanderbilt University Medical Center ( We thank Dr. M. Kay Washington from Vanderbilt University Medical Center for examining intestinal tissue sections from mouse models of colitis.

Author information


  1. Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    • Xi Shen
    • , Liping Liu
    • , Sari A. Acra
    •  & Fang Yan
  2. West China School of Public Health and Healthy Food Evaluation Research Center, Sichuan University, 17 Ren Min South Road, Wuhou District, Chengdu, Sichuan, 610041, China

    • Xi Shen
    •  & Fang He
  3. Department of Medicine, Division of Gastroenterology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    • Richard M. Peek
    • , Keith T. Wilson
    •  & Fang Yan
  4. Department of Pediatrics, Division of Endocrinology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    • Daniel J. Moore
  5. Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, 37232, USA

    • Keith T. Wilson
  6. Departments of Pediatrics and Biochemistry and Molecular Medicine, Children’s Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA, 90027, USA

    • D. Brent Polk
  7. The Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, CA, 90027, USA

    • D. Brent Polk


  1. Search for Xi Shen in:

  2. Search for Liping Liu in:

  3. Search for Richard M. Peek in:

  4. Search for Sari A. Acra in:

  5. Search for Daniel J. Moore in:

  6. Search for Keith T. Wilson in:

  7. Search for Fang He in:

  8. Search for D. Brent Polk in:

  9. Search for Fang Yan in:


X.S., L.L., R.M.P., S.A.A., D.J.M., K.T.W., F.H., D.B.P., and F.Y. designed research studies and analyzed data; X.S., L.L., and F.Y. conducted experiments and acquired data. X.S. R.M.P., S.A.A., D.B.P., and F.Y. wrote the manuscript.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Fang Yan.

Electronic supplementary material

About this article

Publication history